ommercialize products using Emisphere's drug delivery technology, or
Emisphere's ability to fund such efforts with or without partners.
Emisphere undertakes no obligation to update any of these statements.
Readers are cautioned not to place undue reliance on these forward-looking
statements, which speak only as to the date hereof. Accordingly any
forward-looking statements should be read in conjunction with the
additional risks and uncertainties detailed in Emisphere's filings with the
Securities and Exchange Commission, including those factors discussed under
the caption "Risk Factors" in Emisphere's Annual Report on Form 10-K (file
no. 000-17758) filed on March 6, 2007, and our Quarterly Report on Form
10-Q for the quarter ended March 31, 2007, filed on May 7, 2007 (file no.
000-17758).
EMISPHERE TECHNOLOGIES, INC.
Condensed Statements of Operations (Unaudited)
For the three and six months ended June 30, 2007 and 2006
(in thousands, except share and per share data)
For the three months For the six months
ended ended
June 30, June 30,
2007 2006 2007 2006
Revenue $398 $5,220 $3,207 $6,916
Costs and expenses:
Research and development 6,032 4,858 11,484 9,375
General and administrative
expenses 3,638 2,812 7,784 5,614
Depreciation and
amortization 270 972 583 1,962
Total costs and expenses 9,940 8,642 19,851 16,951
Operating loss (9,542) (3,422) (16,644) (10,035)
Other (expense) and income:
Beneficial conversion of
'/>"/>
SOURCE Emisphere Technologies, Inc.
 Copyright©2007 PR Newswire. | |
Page: 1 2 3 4 5 6 7 Related medicine technology :1.
Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery
of GLP-1 and PYY2.
Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial3.
Sygnis Pharma AG announces date for presentation of clinical
results4.
Neose Announces Presentation of Positive Preclinical Data on
GlycoPEGylated Factor VIIa at the XXI Congress of the International
Society on Thrombosis and Haemostasis5.
Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy
of BF-200 ALA In Actinic Keratosis6.
YM BioSciences Announces Secondary Efficacy and Safety Findings in
Randomized Phase IIB Aerolef Trial7.
BioSante Pharmaceuticals Announces New Findings for Potential Bird
Flu Vaccine8.
Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis9.
Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for
Oral Oleoyl-estrone10.
AVI BioPharma Partner Cook Medical Announces Completion of Patient
Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of
Cardiovascular Disease11.
Protox Announces Positive Clinical Data from Prostate Cancer Study